GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Scaled Net Operating Assets

NurExone Biologic (FRA:J90) Scaled Net Operating Assets : 0.13 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NurExone Biologic's operating assets for the quarter that ended in Sep. 2024 was €0.98 Mil. NurExone Biologic's operating liabilities for the quarter that ended in Sep. 2024 was €0.59 Mil. NurExone Biologic's Total Assets for the quarter that ended in Jun. 2024 was €3.06 Mil. Therefore, NurExone Biologic's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.13.


NurExone Biologic Scaled Net Operating Assets Historical Data

The historical data trend for NurExone Biologic's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Scaled Net Operating Assets Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Scaled Net Operating Assets
- -0.12 -0.12

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 -0.23 0.19 0.05 0.13

Competitive Comparison of NurExone Biologic's Scaled Net Operating Assets

For the Biotechnology subindustry, NurExone Biologic's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Scaled Net Operating Assets falls into.



NurExone Biologic Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NurExone Biologic's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(1.494-1.798)/2.638
=-0.12

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1.99 - 0.496
=1.494

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1.817 - 0.002 - 0.017
=1.798

NurExone Biologic's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(0.983-0.59)/3.058
=0.13

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.256 - 2.273
=0.983

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.618 - 0.028 - 0
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines